Pacira Pharma Sees Q4, 2014 Revenues Above Estimates - Quick Facts

(RTTNews) - Specialty pharmaceutical company Pacira Pharmaceuticals, Inc. (PCRX) announced that it expects total revenues for the fourth quarter of $61.8 million, with revenues of $59.0 million for Exparel.

On average, seven analysts polled by Thomson Reuters expect the company to report revenues of $61.52 million for the quarter.

The company also said it anticipates total revenues of $197.7 million for fiscal 2014, with revenues of $188.5 million for Exparel.

Eight Wall Street analysts have a consensus revenue estimate of $197.27 million for the year.

"We are pleased with the continued success of EXPAREL in the fourth quarter, growth over the previous quarter and growth for the year, which we expect to provide the basis of a strong 2015," said Dave Stack, president, chief executive officer and chairman of Pacira.